Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sinopharm Group Co ( (HK:1099) ) has provided an update.
Sinopharm Group Co. Ltd. has announced that its board of directors will meet on August 22, 2025, to consider and approve the unaudited interim results for the first half of the year. This meeting is crucial as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the healthcare industry, focusing on the distribution and retail of pharmaceutical and healthcare products. The company is a significant player in the Chinese market, providing a wide range of medical supplies and services.
Average Trading Volume: 6,297,121
Technical Sentiment Signal: Buy
Current Market Cap: HK$59.07B
For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.